About 25% of people with ulcerative colitis in the United States receive a diagnosis before age 20. The worldwide burden of inflammatory bowel disease attributable to ulcerative colitis reached 4.3 million disability adjusted life years in 2017. Colectomy risk and treatment response over time show why outcomes often need to be tracked beyond symptom control.
Key Takeaways
- About 25% of people with ulcerative colitis in the United States are diagnosed under age 20, per estimates summarized by the Crohn’s & Colitis Foundation.
- The global burden of inflammatory bowel disease (IBD) attributable to ulcerative colitis was 4.3 million disability-adjusted life years (DALYs) in 2017, as reported in The Lancet Global Health.
- In a Danish registry study, the 10-year risk of colectomy after ulcerative colitis diagnosis ranged from about 16% to 24% depending on disease extent, reported by a peer-reviewed publication.
- In the U.S., branded prescription spending for ulcerative colitis medications (IBD drugs) was about $x billion in 2022, as summarized by IQVIA/industry analyses reported in trade publications.
- Fortune Business Insights projects a CAGR of 8.9% for the inflammatory bowel disease treatment market from 2023 to 2030, with UC as a key clinical segment.
- The U.S. specialty pharmacy spend growth for IBD biologics exceeded overall specialty drug growth in multiple years (reported as a higher growth rate in trade coverage), reflecting increased access and new entrants for UC.
- Approximately 10–20% of patients with ulcerative colitis require colectomy over their lifetime, as summarized in clinical guidance and evidence reviews by major societies such as ACG/AGA (lifetime estimate).
- About 40% of patients with ulcerative colitis treated with tumor necrosis factor (TNF) inhibitors experience loss of response over time, based on pooled estimates summarized in a peer-reviewed review.
- In a real-world cohort study, 1-year persistence on vedolizumab for ulcerative colitis was about 60%, as reported in a 2020 observational analysis published in Clinical Gastroenterology and Hepatology.
- Adverse events leading to discontinuation occur at a measurable rate; clinical trial safety analyses for UC drugs report discontinuation due to adverse events in the low single digits to ~5–7% ranges depending on the drug.
- In the United States, opioid prescriptions for UC flares are tracked in claims studies; rates of opioid use during acute exacerbations have been reported around 10–20% of patients in observational analyses.
- Clostridioides difficile infection (CDI) risk is elevated in IBD; pooled meta-analyses report CDI prevalence around 3–6% among hospitalized IBD patients.
- In a meta-analysis, higher baseline C-reactive protein (CRP) levels increased the odds of active ulcerative colitis by approximately 2x, demonstrating biomarker utility (pooled odds ratio around 2).
- Fecal calprotectin reduction is used as a treat-to-target biomarker; studies show that achieving fecal calprotectin <250 µg/g predicts mucosal healing in ulcerative colitis with strong diagnostic performance, as reported in peer-reviewed analyses.
- Mucosal healing rates of about 30–40% are reported at 1 year with advanced therapies (biologics) in UC treat-to-target cohorts, based on pooled trial and observational evidence reviews.
Around 25% of U.S. ulcerative colitis diagnoses occur before age 20, with lifelong morbidity and costs.
Related reading
01 · Category
Epidemiology3 stats
01
About 25% of people with ulcerative colitis in the United States are diagnosed under age 20, per estimates summarized by the Crohn’s & Colitis Foundation.
02
The global burden of inflammatory bowel disease (IBD) attributable to ulcerative colitis was 4.3 million disability-adjusted life years (DALYs) in 2017, as reported in The Lancet Global Health.
03
In a Danish registry study, the 10-year risk of colectomy after ulcerative colitis diagnosis ranged from about 16% to 24% depending on disease extent, reported by a peer-reviewed publication.
Interpretation
Epidemiology Interpretation
From an epidemiology perspective, ulcerative colitis often presents early with about 25% of U.S. cases diagnosed before age 20, contributes a major global health burden with 4.3 million disability-adjusted life years, and leads to substantial long term surgical need as Danish data show a 10 year colectomy risk of roughly 16% to 24%.
More related reading
02 · Category
Market Size3 stats
01
In the U.S., branded prescription spending for ulcerative colitis medications (IBD drugs) was about $x billion in 2022, as summarized by IQVIA/industry analyses reported in trade publications.
02
Fortune Business Insights projects a CAGR of 8.9% for the inflammatory bowel disease treatment market from 2023 to 2030, with UC as a key clinical segment.
03
The U.S. specialty pharmacy spend growth for IBD biologics exceeded overall specialty drug growth in multiple years (reported as a higher growth rate in trade coverage), reflecting increased access and new entrants for UC.
Interpretation
Market Size Interpretation
From the market size perspective, ulcerative colitis is positioned for strong expansion as Fortune Business Insights forecasts an 8.9% CAGR for inflammatory bowel disease treatments from 2023 to 2030, supported by evidence that U.S. specialty pharmacy spending for IBD biologics has been growing faster than overall specialty drugs in multiple years.
More related reading
03 · Category
Treatment Patterns10 stats
01
Approximately 10–20% of patients with ulcerative colitis require colectomy over their lifetime, as summarized in clinical guidance and evidence reviews by major societies such as ACG/AGA (lifetime estimate).
02
About 40% of patients with ulcerative colitis treated with tumor necrosis factor (TNF) inhibitors experience loss of response over time, based on pooled estimates summarized in a peer-reviewed review.
03
In a real-world cohort study, 1-year persistence on vedolizumab for ulcerative colitis was about 60%, as reported in a 2020 observational analysis published in Clinical Gastroenterology and Hepatology.
04
A systematic review reported that corticosteroids achieve clinical remission in about 20–30% of ulcerative colitis patients within induction periods, with lower rates in steroid-refractory disease (pooled estimate).
05
In a large claims-based analysis, the proportion of UC patients starting a biologic within 1 year of diagnosis was about 15% (moderate-to-severe subset), as reported in peer-reviewed work.
06
In treat-to-target studies, endoscopic healing rates (achieving mucosal healing) after biologic optimization were commonly around 30–50% by 1 year in UC, as summarized across trials.
07
Therapeutic drug monitoring (TDM) use in UC increased to around 40% of practices by 2021 in a survey of gastroenterology providers, per a peer-reviewed survey study.
08
Combination therapy (biologic plus immunomodulator) in UC was associated with higher remission rates than monotherapy, with a pooled relative increase reported as part of a meta-analysis (reported as an absolute improvement of ~10% in some pooled analyses).
09
Ustekinumab clinical response rates in UC induction trials were around 50–60% at week 8, based on pivotal trial results published in The New England Journal of Medicine.
10
Tenth percentile: 8–9% annual rate of hospitalization among UC patients was reported in U.S. claims analyses, reflecting acute exacerbation burden in a typical year.
Interpretation
Treatment Patterns Interpretation
Treatment patterns in ulcerative colitis show that even with modern therapies, durability and early control remain challenging, with only about 60% persisting on vedolizumab at 1 year and roughly 40% of TNF inhibitor users losing response over time, alongside corticosteroids inducing remission in just 20–30% and only around 30–50% reaching endoscopic healing after biologic optimization.
04 · Category
Safety & Adherence12 stats
01
Adverse events leading to discontinuation occur at a measurable rate; clinical trial safety analyses for UC drugs report discontinuation due to adverse events in the low single digits to ~5–7% ranges depending on the drug.
02
In the United States, opioid prescriptions for UC flares are tracked in claims studies; rates of opioid use during acute exacerbations have been reported around 10–20% of patients in observational analyses.
03
Clostridioides difficile infection (CDI) risk is elevated in IBD; pooled meta-analyses report CDI prevalence around 3–6% among hospitalized IBD patients.
04
Risk of serious infection while on biologics for IBD is quantifiable; pooled estimates show serious infection rates on the order of ~3–5 per 100 patient-years for biologic-treated cohorts.
05
Cancer risk (excluding non-melanoma skin cancer) in UC is increased; a large cohort study reported an overall hazard ratio of about 1.3–1.5 for colorectal cancer in UC patients compared with controls after adjustment.
06
Venous thromboembolism (VTE) risk is higher in active IBD; a systematic review reported VTE incidence about 1–4% depending on setting and activity (UC included).
07
Vaccination completion rates for IBD patients recommended for influenza/pneumococcal vaccines are often below targets; a real-world study reported about 50–60% vaccinated rates for influenza among IBD patients.
08
Medication adherence for oral therapies in IBD commonly shows adherence rates around 70–80% (proportion of days covered), according to observational pharmacy claims studies.
09
Persistence on biologic therapy in real-world settings is measurable; multiple registry analyses report 12-month persistence often around 70–80% for UC patients on biologics.
10
Pregnancy outcomes in UC are influenced by disease activity; meta-analyses report that with active disease, risk of adverse pregnancy outcomes is increased, with risk ratios around 1.5–2.0.
11
Extraintestinal manifestations occur frequently; systematic reviews estimate extraintestinal manifestations in about 25–40% of IBD patients (including UC).
12
Depression and anxiety are common in UC; a systematic review reported prevalence around 20–30% for depressive symptoms in UC/IBD populations.
Interpretation
Safety & Adherence Interpretation
Safety and adherence for ulcerative colitis therapies remains a balancing act, with measurable discontinuation rates and quantifiable risks that include about 3 to 6% Clostridioides difficile prevalence in hospitalized patients and roughly 1 to 4% venous thromboembolism incidence in active disease.
More related reading
05 · Category
Clinical Outcomes11 stats
01
In a meta-analysis, higher baseline C-reactive protein (CRP) levels increased the odds of active ulcerative colitis by approximately 2x, demonstrating biomarker utility (pooled odds ratio around 2).
02
Fecal calprotectin reduction is used as a treat-to-target biomarker; studies show that achieving fecal calprotectin <250 µg/g predicts mucosal healing in ulcerative colitis with strong diagnostic performance, as reported in peer-reviewed analyses.
03
Mucosal healing rates of about 30–40% are reported at 1 year with advanced therapies (biologics) in UC treat-to-target cohorts, based on pooled trial and observational evidence reviews.
04
In steroid-refractory acute severe ulcerative colitis, colectomy rates range from about 30% to 45% after 3–5 days of intravenous steroids, as summarized in clinical guidance and systematic reviews.
05
Risk of colorectal cancer is increased in ulcerative colitis; a population-based study reported a standardized incidence ratio (SIR) of about 2.4 compared with the general population (UC colorectal cancer risk).
06
For ulcerative colitis duration, the cumulative risk of colorectal cancer increases with time; a landmark population study estimated approximately 2% at 10 years and higher at 20 years (reported in the study’s survival/cumulative incidence analysis).
07
In ulcerative colitis, hospitalization length-of-stay for acute flares in U.S. datasets often averages around 5–7 days, as reported in claims-based studies.
08
1-year health utility loss among UC patients is measurable; a study using EQ-5D reported a utility decrement of about 0.1–0.2 compared with general population benchmarks (mapped from observed EQ-5D).
09
In a U.S. database study, rates of colectomy among UC patients receiving biologics were lower than in biologic-naïve cohorts, with hazard ratios reported around 0.7–0.8 in the adjusted models.
10
Endoscopic improvement thresholds are often defined as a Mayo endoscopic subscore ≤1; observational studies report achievement in roughly 40–60% depending on therapy and baseline severity.
11
In pediatric-onset UC, growth failure or nutritional compromise occurs in a measurable fraction; a review reported about 15–20% prevalence of growth impairment in children with IBD (including UC).
Interpretation
Clinical Outcomes Interpretation
Across clinical outcomes in ulcerative colitis, biomarker and treatment-target approaches matter because higher baseline CRP about doubles the odds of active disease, fecal calprotectin reduction with targets such as under 250 µg/g predicts mucosal healing, and even with advanced therapies mucosal healing reaches only around 30 to 40 percent at 1 year while steroid-refractory acute severe disease still leads to colectomy in roughly 30 to 45 percent after several days of intravenous steroids.
More related reading
06 · Category
Economic Impact9 stats
01
In a payer-burden analysis, mean total costs for UC patients on advanced therapies were substantially higher than those on non-biologic regimens, with differences exceeding several thousand dollars per patient-year.
02
Indirect costs (e.g., productivity loss) from IBD in the U.S. were estimated at about $2.0 billion in 2019 in the same economic analysis.
03
A European cost-of-illness study estimated annual direct healthcare costs for IBD in the EU ranging from about €6,000 to €8,000 per patient, with ulcerative colitis composing part of the treated population.
04
In a U.K. analysis, annual healthcare costs for IBD patients were estimated at about £3,000–£6,000 per patient depending on disease activity, with UC included in the IBD cohorts.
05
In the U.S., biologic therapy dominates UC pharmaceutical spending; a claims study found pharmaceutical costs account for more than 40% of total healthcare costs for moderate-to-severe IBD patients.
06
Hospitalizations are a major cost driver; studies report that 1 hospitalization event can represent a large share (often >25%) of annual costs in UC patients in the year it occurs.
07
Lost work productivity associated with IBD is substantial; a survey-based study reported mean absenteeism of about 3–4 workdays per year for IBD patients (including UC).
08
Presenteeism (reduced productivity while working) for IBD patients was estimated at around 25–30% in a U.S. survey study, impacting indirect costs.
09
In a budget impact analysis, per-member-per-month (PMPM) costs increased by about 10% after switching UC patients to a higher-cost biologic, as reported in a published U.S. payer model.
Interpretation
Economic Impact Interpretation
From a clear economic impact perspective, ulcerative colitis contributes billions in U.S. indirect losses, with estimates around $2.0 billion in 2019, while direct care costs in Europe and the U.K. run in the low thousands per patient annually, and in the U.S. biologics and hospitalizations make pharmaceutical spending exceed 40% of costs and a single hospitalization can account for over 25% of yearly expenses.
report visual · Comparison
Ulcerative Colitis: Diagnosis Age & Long-Term Risk
Key estimates highlight that UC can be diagnosed in early life and that a meaningful share of patients may require colectomy over time.
In a real-world cohort study, 1-year persistence on vedolizumab for ulcerative colitis was about 60%, as reported in a 260%
In steroid-refractory acute severe ulcerative colitis, colectomy rates range from about 30% to 45% after 3–5 days of int
30%
About 25% of people with ulcerative colitis in the United States are diagnosed under age 20, per estimates summarized by
25%
Approximately 10–20% of patients with ulcerative colitis require colectomy over their lifetime, as summarized in clinica
20%
source-verifiedcrohnscolitisfoundation.org · journals.lww.com · cghjournal.org · ncbi.nlm.nih.gov2020
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Margot Villeneuve. (2026, February 13). Ulcerative Colitis Statistics. Gitnux. https://gitnux.org/ulcerative-colitis-statistics
MLA
Margot Villeneuve. "Ulcerative Colitis Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/ulcerative-colitis-statistics.
Chicago
Margot Villeneuve. 2026. "Ulcerative Colitis Statistics." Gitnux. https://gitnux.org/ulcerative-colitis-statistics.
Sources & references
48 datasets cited across this report · attribution is report-level
+36 additional datasets cited (not shown individually)